20/20 Biolabs, Inc.
AIDX· Nasdaq
AIDX20/20 Biolabs, Inc.
Filed Aug 14, 2026 · 10-Q · 45 days after period end · 0001213900-26-090042
| Metric | Q2 2026 | Q2 2025 |
|---|---|---|
| Revenue | $730.57K | $535.06K |
| Net Income | -$1.51M | -$840.93K |
| EPS Diluted | -$0.26 | -$0.17 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
20/20 Biolabs, Inc. · CIK 1139685 · Engraved from SEC EDGAR
ended Jun 30, 2026 · filed Aug 14, 2026 · 45 d after period end
